Melike Ozcelik
Overview
Explore the profile of Melike Ozcelik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
190
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kahraman S, Erul E, Seyyar M, Gumusay O, Bayram E, Demirel B, et al.
Future Oncol
. 2023 May;
19(10):727-736.
PMID: 37133230
Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The authors report retrospective...
12.
Odabas H, Dogan A, Ozcelik M, Yildirim S, Ozkerim U, Turan N, et al.
Medicina (Kaunas)
. 2023 Mar;
59(3).
PMID: 36984558
This investigation aimed to determine the impacts of concurrent proton pump inhibitors (PPIs) on progression-free survival (PFS) in patients with hormone receptor-positive and HER2-negative metastatic breast cancer managed with palbociclib...
13.
Erol C, Sakin A, Basoglu T, Ozden E, Cabuk D, Dogan M, et al.
Turk J Med Sci
. 2022 Nov;
52(4):1022-1032.
PMID: 36326360
Background: Perioperative FLOT regimen is a standard of care in locally advanced operable gastric and GEJ adenocarcinoma. We aimed to determine the efficacy, prognostic factors of perioperative FLOT chemotherapy in...
14.
Koca S, Koca E, Okten I, Orengul F, Ozturk A, Ozcelik M, et al.
Heliyon
. 2022 Aug;
8(8):e10142.
PMID: 35996550
Introduction: Although cancer patients have a high risk of exposing COVID-19 and developing severe complications, they have to receive active treatment. We aimed to determine the psychological conditions of cancer...
15.
Koyuncuer A, Sayar S, Zemheri I, Ozdil K, Ozcelik M
Diagn Cytopathol
. 2022 Jun;
50(10):E295-E300.
PMID: 35656642
Metastases to the pancreas are rare and can be confused with the primary adenocarcinoma of the pancreas. Metastasis of renal pelvis urothelial carcinomas to the pancreas are extremely rare. Endoscopic...
16.
Basoglu T, Sakin A, Erol C, Ozden E, Cabuk D, Cilbir E, et al.
J Chemother
. 2022 May;
35(2):142-149.
PMID: 35579894
Neoadjuvant chemotherapy (NACT) in gastroesophageal junction (GEJ) and gastric cancer (GC) was shown to improve survival in recent studies. We aimed to share our real-life experience of patients who received...
17.
Akturk Esen S, Ergun Y, Erol C, Arikan R, Er M, Atci M, et al.
Bosn J Basic Med Sci
. 2022 Apr;
22(5):818-825.
PMID: 35460397
Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma. However, there is no comprehensive study on which platinum-based treatment should be preferred. This study aimed to...
18.
Yasin A, Goktas Aydin S, Sumbul B, Koral L, Simsek M, Geredeli C, et al.
Future Oncol
. 2022 Jan;
18(10):1235-1244.
PMID: 35081732
To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Spike IgG antibodies against SARS-CoV-2 were measured in blood...
19.
Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan O, Ayhan M
J Coll Physicians Surg Pak
. 2021 Oct;
31(11):1308-1313.
PMID: 34689488
Objective: To compare the overall survival and progression-free survival of front-line cytoreductive surgery (CRs) ± hyperthermic intraperitoneal chemotherapy versus intensive systemic chemotherapy alone, in patients with isolated peritoneal carcinomatosis of...
20.
Celik M, Ozcelik S, Bas S, Sariaydin M, Ozcelik M, Gozu H
Arch Endocrinol Metab
. 2021 Sep;
65(5):617-624.
PMID: 34591405
Objective: We aimed to investigate the role of testosterone to estradiol ratio in predicting the effectiveness of human chorionic gonadotropin and testosterone treatments in male hypogonadism. Methods: Thirty-six male patients...